MedTrace Logo

Twin SUBLIVAC® Grasses Clinical Efficacy Study

NCT00422149 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2012-02-07

No results posted yet for this study

Summary

To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.

Conditions

  • Rhinitis, Allergic, Seasonal
  • Conjunctivitis, Allergic

Interventions

DRUG

SUBLIVAC® Grasses/Placebo treatment

SUBLIVAC® Grasses/Placebo treatment

DRUG

SUBLIVAC® Grasses treatment

SUBLIVAC® Grasses treatment

DRUG

Placebo treatment

Placebo treatment

Sponsors & Collaborators

  • HAL Allergy

    lead INDUSTRY

Principal Investigators

  • R Peter, Prof.Dr.med · Zentrum für Klinische Forschung, Helholzstrasse 8/1, 89081 Ulm, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Belgium
  • Germany
  • Netherlands
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422149 on ClinicalTrials.gov